trending Market Intelligence /marketintelligence/en/news-insights/trending/bziyyav3aifhyggtvsog8q2 content esgSubNav
In This List

Roivant Sciences snaps up PhaseRx in bankruptcy auction

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roivant Sciences snaps up PhaseRx in bankruptcy auction

PhaseRx, Inc. said it entered an asset purchase agreement with N.Y.-based privately held drugmaker Roivant Sciences, Inc. following the auction of company's assets.

U.S.-based PhaseRx had filed for Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware in December 2017.

An auction for substantially all of the company's assets concluded Jan. 31, with Roivant Sciences' German unit selected as the highest and best bid.

The bid consists of a purchase price of $800,000 plus the assumption of certain liabilities and a note between Roivant and PhaseRx's senior secured lender Hercules Capital Inc.

The note includes milestone payments to pay down the Hercules' secured debt, among other items.

PhaseRx said all proceeds from the auction will be used to satisfy its liabilities to the creditors.

The sale is expected to close Feb. 2, subject to the satisfaction of customary closing conditions, including approval by the bankruptcy court.